Skip to content
value.today

ICO Therapeutics Inc.

Total raised
$64 M
4 rounds on record
Latest round
$25 M
Dec 2024
First round on record
Oct 2009
Today
Went public
See the company page

ICO Therapeutics Inc. is listed today as Satellos Bioscience Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of ICO Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2024$25 MNo. 4$10 to $50 million

ICO Therapeutics Inc.: Raise no. 4, Dec 2024

Investors in this round

13 investors had bought by the notice of Jan 3, 2025: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,736,980
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • Courtney D. Wells · Executive Officer
  • Elizabeth Williams · Executive Officer
  • Frank Gleeson · Executive Officer, Director, Promoter
  • Michael Robert Cross · Executive Officer
  • Michael Rudnicki · Executive Officer
  • Philip D. Lambert · Executive Officer
  • Adam Mostafa · Director
  • Bill Jarosz · Director
  • Brian Bloom · Director
  • Franklin D. Berger · Director
  • Geoff MacKay · Director
  • Rima Al-awar · Director
  • Stephanie D. Brown · Director
  • William McVicar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Haywood Securities (USA) Inc. (CRD 42072) · Vancouver, British Columbia, CanadaSold in CA, CT, MA, NY, OR
  • Canaccord Genuity LLC (CRD 1020) · New York, New YorkSold in NY

Signed by Elizabeth Williams, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 3, 2025. Read the notice at the SEC.

equity, optionsSEC
May 2023$33 MNo. 3$10 to $50 million

ICO Therapeutics Inc.: Raise no. 3, May 2023

Investors in this round

16 investors had bought by the notice of May 25, 2023: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$33 M of $33 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,244,313
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • Frank Gleeson · Executive Officer, Director, Promoter
  • J. Robert Hall · Executive Officer
  • Michael Rudnicki · Executive Officer
  • Philip D. Lambert · Executive Officer
  • Warren Whitehead · Executive Officer
  • Adam Mostafa · Director
  • Bill Jarosz · Director
  • Brian Bloom · Director
  • Geoff MacKay · Director
  • Rima Al-awar · Director
  • William McVicar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Haywood Securities (USA) Inc. (CRD 42072) · Vancouver, British Columbia, CanadaSold in CT, MD, NY, TX, WA

Signed by Frank Gleeson, President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 25, 2023. Read the notice at the SEC.

equity, optionsSEC
Jan 2014$2 MNo. 2$2 to $10 million

ICO Therapeutics Inc.: Raise no. 2, Jan 2014

Investors in this round

2 investors had bought by the notice of Feb 5, 2014: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $8 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Each unit is comprised of one common share and three-quarters of one share purchase warrant. Each whole warrant is exercisable for one common share at an exercise price of Cdn$0.539 for a period of fi
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
$266,096
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Andrew J. Rae · Executive Officer, Director
  • Peter G. Hnik · Executive Officer
  • W. John Meekison · Executive Officer
  • Douglas G. Janzen · Director
  • Noel J. Hall · Director
  • Richard J. Barker · Director
  • William J. Jarosz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On the amounts: “The additional $5,903,289 may be received by the exercise of share purchase warrants sold inside and outside the U.S. U.S. dollar amounts are based on the Bank of Canada noon rate of exchage reported on January 27, 2014, which was Cdn$1.1098=US$1.00.”
  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by John Meekison, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 5, 2014. Read the notice at the SEC.

equity, optionsSEC
Oct 2009$3 MNo. 1$2 to $10 million

ICO Therapeutics Inc.: Raise no. 1, Oct 2009

Investors in this round

5 investors had bought by the notice of Dec 1, 2009: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
$264,249
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Andrew John Rae · Executive Officer, Director
  • John John Clement · Executive Officer, Director
  • Peter John Hnik · Executive Officer
  • Santa Jeremy John Ono · Executive Officer
  • W. John Meekison · Executive Officer
  • Noel John Hall · Director
  • Richard John Barker · Director
  • William John Jarosz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Versant Partners USA, Inc. (CRD 135167) · Montreal, A8Sold in no state named
  • Loewen, Ondaatje, McCutcheon USA Limited (CRD 35205) · Toronto, A6Sold in no state named

Remarks in the notice

  • On fees: “Placement agents will receive finders fees equal to 8% of the total offering amount. U.S. dollar amount is based on conversion rate of 1 CAD = 0.939651 USA (October 27, 2009).”
  • On the amounts: “U.S. dollar amount is based on conversion rate of 1 CAD = 0.939651 USD (October 27, 2009).”

Signed by W. John Meekison, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 1, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • ICO Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2025).

    SEC Form D · Jan 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2025

That is all the official record says: ICO Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of ICO Therapeutics Inc. are on record.

Investors#

No investor of ICO Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 16 investors.

Largest shareholders today

Institutions holding Satellos Bioscience Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by ICO Therapeutics Inc.
NameRoleNamed in
Courtney D. WellsExecutive officerJan 2025
Elizabeth WilliamsExecutive officerJan 2025
Frank GleesonExecutive officerJan 2025
Michael Robert CrossExecutive officerJan 2025
Michael RudnickiExecutive officerJan 2025
Philip D. LambertExecutive officerJan 2025
J. Robert HallExecutive officerMay 2023
Warren WhiteheadExecutive officerMay 2023
Andrew J. RaeExecutive officerFeb 2014
Peter G. HnikExecutive officerFeb 2014
W. John MeekisonExecutive officerFeb 2014
Andrew John RaeExecutive officerDec 2009
John John ClementExecutive officerDec 2009
Peter John HnikExecutive officerDec 2009
Santa Jeremy John OnoExecutive officerDec 2009
Adam MostafaDirectorJan 2025
Bill JaroszDirectorJan 2025
Brian BloomDirectorJan 2025
Frank GleesonDirectorJan 2025
Franklin D. BergerDirectorJan 2025
Geoff MacKayDirectorJan 2025
Rima Al-awarDirectorJan 2025
Stephanie D. BrownDirectorJan 2025
William McVicarDirectorJan 2025
Andrew J. RaeDirectorFeb 2014
Douglas G. JanzenDirectorFeb 2014
Noel J. HallDirectorFeb 2014
Richard J. BarkerDirectorFeb 2014
William J. JaroszDirectorFeb 2014
Andrew John RaeDirectorDec 2009
John John ClementDirectorDec 2009
Noel John HallDirectorDec 2009
Richard John BarkerDirectorDec 2009
William John JaroszDirectorDec 2009
Frank GleesonPromoterJan 2025

Went public since 2026. Its SEC number is that of a company listed on a stock exchange.